Semax vs Adamax: What’s the Difference?

Semax is a synthetic peptide derived from a fragment of ACTH (adrenocorticotropic hormone), with an added Pro-Gly-Pro sequence for stability. It was developed by Russian scientists and has been registered in Russia since 1994 for cerebrovascular conditions.

In Russia, Semax is on the government’s list of vital and essential medicines and is used for:

• Ischemic stroke recovery
• Transient ischemic attack
• Cognitive and memory disorders
• Optic nerve disease

Semax is not FDA-approved in the United States.

Adamax is a designer analog of Semax. It takes the Semax backbone and adds two chemical modifications borrowed from another experimental peptide, P021 (P21):

• An N-terminal acetyl group, the same idea behind N-Acetyl Semax
• A C-terminal adamantane group, a bulky, fat-soluble “cage” structure

Adamax has no approved medical use anywhere. It has been identified as a designer drug in border seizures, and New Zealand’s medicines regulator has suggested classifying it as a prescription medicine.

The core difference between Semax and Adamax is chemical modification.

Why Add Adamantane?

Adamantane is a highly lipophilic (fat-soluble) structure. The adamantane modification is intended to:

• Improve stability by slowing enzymatic breakdown
• Increase membrane permeability
• Improve blood-brain barrier penetration
• Extend duration of action compared with Semax

These are design goals. They haven’t been confirmed in published human studies.

Semax’s exact mechanism isn’t fully understood, but research points to several pathways:

• BDNF and TrkB signaling: In a 2006 rat study published in Brain Research, intranasal Semax produced about a 1.4-fold increase in BDNF (brain-derived neurotrophic factor) in the hippocampus, along with increased TrkB activation.
• Melanocortin receptors: Some evidence suggests Semax acts through these receptors.
• Neurotransmitter modulation: Research suggests effects on dopamine and serotonin systems.
• Enzyme inhibition: Semax may inhibit enzymes that break down enkephalins.

Adamax is assumed to work through the same pathways as Semax, especially BDNF/TrkB signaling, with potentially stronger or longer-lasting effects because of its modifications.

However, nearly all claims about Adamax are extrapolated from Semax research. Findings from Semax studies belong to Semax, not to Adamax.

Semax has a meaningful but limited research base:

• Stroke recovery: In a study of 110 post-ischemic stroke patients, Semax combined with rehabilitation was associated with higher BDNF levels and improved recovery scores. The study was not randomized or placebo-controlled.
• Cognition: Russian studies report improvements in attention and memory, but many aren’t indexed in Western databases.
• Animal research: Mechanistic findings, including BDNF upregulation, have been more widely replicated.

Limitations of Semax Research

• Most studies come from a small number of Russian research groups.
• Many are published in Russian-language journals.
• As of late 2023, there were no published human trials of Semax outside Russia and post-Soviet countries.
• Long-term safety data outside Russia are sparse.

There are no published human clinical trials on Adamax. Its proposed benefits, including enhanced cognition, focus, and neuroprotection, are based on:

• Semax research
• The theoretical effects of its chemical modifications
• Anecdotal reports

There’s no independent validation that Adamax is more effective, longer-lasting, or as well tolerated as Semax.

Semax: Generally described as well tolerated in Russian research. The most commonly reported side effect is mild nasal irritation from intranasal use. Some people also report headache, stimulant-like effects, or mood changes.

Adamax: No formal safety data exist. Its side effect profile is assumed to resemble Semax’s, but structural changes can alter how a compound behaves in the body, so this can’t be assumed.

Both compounds are sold online as research chemicals in many countries. These products aren’t regulated like approved medications, and their identity, purity, and dose can’t be guaranteed without independent testing.

Semax has substantially more evidence. It has decades of Russian clinical use, human stroke studies, and replicated animal research.

Adamax is largely untested. Its potential advantages are theoretical and based on chemistry rather than clinical data.

If evidence quality matters to you, Semax is the more studied compound, though even its evidence is limited by Western standards.

• What is the difference between Semax and Adamax? Adamax is a modified version of Semax with an added acetyl group and adamantane group, intended to improve stability and brain penetration.
• Is Adamax stronger than Semax? It’s marketed that way, but there’s no published human research confirming Adamax is stronger or longer-lasting.
• Is Semax FDA-approved? No. Semax is registered in Russia but is not FDA-approved in the US.
• Is Adamax safe? Its safety hasn’t been studied in humans. Claims about its tolerability are extrapolated from Semax.
• What is the difference between Adamax and N-Acetyl Semax? Both add an acetyl group to Semax. Adamax also adds an adamantane group.
• Does Semax increase BDNF? Animal research shows Semax increases BDNF in the hippocampus, and a Russian stroke study linked it to higher BDNF levels in patients.

• Adamax is a designer analog of Semax with acetyl and adamantane modifications.
• Semax has Russian clinical use and human stroke research; Adamax has no published human studies.
• Both are thought to act on BDNF/TrkB signaling.
• Neither is FDA-approved, and both are prohibited in WADA-tested sports.
• Adamax’s claimed advantages over Semax are theoretical.

• Wikipedia – Adamax
• Wikipedia – Semax
• Superpower – Semax: An ACTH-Derived Heptapeptide
• Outliyr – Semax Research Report
• Peptide Dosing Protocols – Adamax Overview
• Doctronic – Semax for Focus and Recovery